Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate.
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.
Health Law Institute, University of Alberta, Edmonton, Alberta, Canada.
Timothy
T
Caulfield
Jim
J
Evans
Amy
A
McGuire
Christopher
C
McCabe
Tania
T
Bubela
Robert
R
Cook-Deegan
Jennifer
J
Fishman
Stuart
S
Hogarth
Fiona A
FA
Miller
Vardit
V
Ravitsky
Barbara
B
Biesecker
Pascal
P
Borry
Mildred K
MK
Cho
June C
JC
Carroll
Holly
H
Etchegary
Yann
Y
Joly
Kazuto
K
Kato
Sandra Soo-Jin
SS
Lee
Karen
K
Rothenberg
Pamela
P
Sankar
Michael J
MJ
Szego
Pilar
P
Ossorio
Daryl
D
Pullman
Francois
F
Rousseau
Wendy J
WJ
Ungar
Brenda
B
Wilson
D015894:Genome, Human; D023281:Genomics / Q000191:economics* / Q000331:legislation & jurisprudence; D006291:Health Policy; D059014:High-Throughput Nucleotide Sequencing / Q000191:economics*; D006801:Humans; D011639:Public Opinion; D017422:Sequence Analysis, DNA / Q000191:economics*; D014481:United States